Nath Bio-Genes Board Meeting May 4 & Earnings Call May 5 for Q4FY26 Results
Nath Bio-Genes has scheduled a comprehensive Q4FY26 results disclosure process with board meeting on May 4, 2026 to approve audited financial results and consider dividend recommendations, followed by earnings conference call on May 5, 2026 at 4:00 PM IST hosted by Go India Advisors featuring key management personnel including MD Satish Kagliwal and CFO Amol Gupta.
*this image is generated using AI for illustrative purposes only.
Nath Bio-Genes (India) Limited has announced a comprehensive schedule for its Q4FY26 financial results disclosure, including a board meeting on May 4, 2026, followed by an earnings conference call on May 5, 2026. The company issued the board meeting intimation on April 25, 2026, and earnings call notification on April 29, 2026, in compliance with SEBI regulations.
Board Meeting Agenda
The board meeting scheduled for May 4, 2026, will address several critical matters for the company's financial year 2025-26:
| Agenda Item: | Details |
|---|---|
| Financial Results: | Audited Financial Results (Standalone and Consolidated) for Q4 and FY ended March 31, 2026 |
| Dividend Consideration: | Recommendation of dividend for FY 2025-26, subject to shareholder approval at AGM |
| Additional Business: | Any other business with board permission |
Earnings Conference Call Details
Following the board meeting, Nath Bio-Genes will conduct an earnings conference call hosted by Go India Advisors. The call is scheduled for May 5, 2026, at 4:00 PM IST to discuss the Q4FY26 and full-year results.
| Parameter: | Details |
|---|---|
| Date & Time: | May 5, 2026 at 4:00 PM IST |
| Host: | Go India Advisors |
| Dial-in Numbers: | 086 3416 8887 / 086 4536 7331 |
| Registration: | Pre-registration available for Diamond Pass access |
Management Participation
Key management personnel will participate in the earnings conference call:
| Position: | Name |
|---|---|
| Managing Director: | Mr. Satish Kagliwal |
| Executive Vice President: | Dr. Devinder Khurana |
| Chief Financial Officer: | Mr. Amol Gupta |
| Sales Lead: | Mr. Harish Pandey |
| Research Lead: | Mr. Venkatesh Kulkarni |
Trading Window and Compliance
In accordance with the company's Code of Conduct for prevention of Insider Trading, Nath Bio-Genes has implemented a trading window closure from March 31, 2026, until May 6, 2026. The announcements were made pursuant to Regulations 29, 30, and 33 of the SEBI Listing Regulations 2015, with notifications communicated to both BSE and NSE where the company is listed.
The structured approach to results disclosure demonstrates Nath Bio-Genes' commitment to transparency and regulatory compliance as it concludes financial year 2025-26.
Historical Stock Returns for Nath Bio-Genes
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.12% | +2.17% | -0.49% | +3.00% | -12.26% | -59.12% |
What key performance metrics and growth drivers will investors focus on during the Q4FY26 earnings call to assess Nath Bio-Genes' competitive position in the biotechnology sector?
How might the dividend recommendation decision impact Nath Bio-Genes' stock price and investor sentiment in the upcoming trading sessions?
What strategic initiatives or expansion plans is Nath Bio-Genes likely to announce for FY27 given the comprehensive management participation in the earnings call?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
